Skip to main content
Premium Trial:

Request an Annual Quote

SomaLogic, AmberGen Pen Reagent Deal

NEW YORK (GenomeWeb News) – AmberGen will provide its proprietary photocleavable biotin reagent for the commercial use with SomaLogic's Somascan technology platform under a deal announced on Tuesday.

Specifically, Ambergen is licensing its 5-prime photocleavable biotin, a light-activated biomolecule, to SomaLogic. Terms of the deal were not disclosed.

"AmberGen's photocleavable biotin element provides an efficient way to detect and measure the bound proteins as part of our Somascan platform," SomaLogic Chief Technology Officer Nick Saccomano said in a statement.

SomaLogic's Somascan and Somamer technologies were developed to achieve necessary sensitivity on a high-throughput proteomic quantitation platform. The Somascan technology uses Somamers, or Slow Off-rate Modified Aptamers, for the screening of dozens of patient samples simultaneously "allowing quantification of many specific proteins in a multiplexed, high-throughput manner," the company said.

Last month, SomaLogic inked a deal with Novartis for use of its proteomics technologies for Novartis' drug discovery and development efforts.

The Scan

And Back

The New York Times reports that missing SARS-CoV-2 genome sequences are back in a different database.

Lacks Family Hires Attorney

A lawyer for the family of Henrietta Lacks plans to seek compensation from pharmaceutical companies that have used her cancer cells in product development, the Baltimore Sun reports.

For the Unknown

The Associated Press reports that family members are calling on the US military to use new DNA analysis techniques to identify unknown sailors and Marines who were on the USS Arizona.

PLOS Papers on Congenital Heart Disease, COVID-19 Infection Host MicroRNAs, Multiple Malformation Mutations

In PLOS this week: new genes linked to congenital heart disease, microRNAs with altered expression in COVID-19, and more.